BACKGROUND: The role of human papillomavirus (HPV) in sinonasal inverted papillomas (IPs) is controversial. Determining the prevalence of HPV infection and its impact on the molecular biology of these tumors is critical to characterizing its role in the pathogenesis of IPs. METHODS: A total of 112 paraffin-embedded IPs from 90 patients were studied. A tissue microarray was constructed and stained for p16, p53, epidermal growth factor receptor (EGFR), and cyclin D1. HPV presence and types were determined using PGMY 09/11 primers and integration using HPV 11 detection of integrated papillomavirus sequences by ligation-mediated polymerase chain reaction (DIPS-PCR). RESULTS: HPV was detected in 11 of 90 (12%) patients. HPV 11 was found in 9 samples. HPV 6 and HPV 27 were found in 1 sample each. EGFR staining proportion was higher in HPV-positive IPs vs HPV-negative specimens (56.2% vs 23.6%; p = 0.009). Differences in p16, p53, and cyclin D1 staining were not significant. HPV-positive lesions tend to progress to malignancy (p = 0.064). Three samples were analyzed for integration. Viral integration was found in both malignant tumors but not in the precursor IP. CONCLUSION: Degradation of p53 and p16/cyclin D1 dysregulation are not important mechanisms in low-risk HPV-related IP. The low prevalence of HPV in this series indicates it is not a main etiological factor for IPs; however, when present, low-risk HPV may contribute to the biology of IPs through an increase of EGFR expression and a predisposition for malignant progression by integration into the cellular genome.
BACKGROUND: The role of human papillomavirus (HPV) in sinonasal inverted papillomas (IPs) is controversial. Determining the prevalence of HPV infection and its impact on the molecular biology of these tumors is critical to characterizing its role in the pathogenesis of IPs. METHODS: A total of 112 paraffin-embedded IPs from 90 patients were studied. A tissue microarray was constructed and stained for p16, p53, epidermal growth factor receptor (EGFR), and cyclin D1. HPV presence and types were determined using PGMY 09/11 primers and integration using HPV 11 detection of integrated papillomavirus sequences by ligation-mediated polymerase chain reaction (DIPS-PCR). RESULTS:HPV was detected in 11 of 90 (12%) patients. HPV 11 was found in 9 samples. HPV 6 and HPV 27 were found in 1 sample each. EGFR staining proportion was higher in HPV-positive IPs vs HPV-negative specimens (56.2% vs 23.6%; p = 0.009). Differences in p16, p53, and cyclin D1 staining were not significant. HPV-positive lesions tend to progress to malignancy (p = 0.064). Three samples were analyzed for integration. Viral integration was found in both malignant tumors but not in the precursor IP. CONCLUSION: Degradation of p53 and p16/cyclin D1 dysregulation are not important mechanisms in low-risk HPV-related IP. The low prevalence of HPV in this series indicates it is not a main etiological factor for IPs; however, when present, low-risk HPV may contribute to the biology of IPs through an increase of EGFR expression and a predisposition for malignant progression by integration into the cellular genome.
Authors: P E Gravitt; C L Peyton; T Q Alessi; C M Wheeler; F Coutlée; A Hildesheim; M H Schiffman; D R Scott; R J Apple Journal: J Clin Microbiol Date: 2000-01 Impact factor: 5.948
Authors: F Luft; R Klaes; M Nees; M Dürst; V Heilmann; P Melsheimer; M von Knebel Doeberitz Journal: Int J Cancer Date: 2001-04-01 Impact factor: 7.396
Authors: G S Akerman; W H Tolleson; K L Brown; L L Zyzak; E Mourateva; T S Engin; A Basaraba; A L Coker; K E Creek; L Pirisi Journal: Cancer Res Date: 2001-05-01 Impact factor: 12.701
Authors: Heather M Walline; Chris Komarck; Jonathan B McHugh; Serena A Byrd; Matthew E Spector; Samantha J Hauff; Martin P Graham; Emily Bellile; Jeffrey S Moyer; Mark E Prince; Gregory T Wolf; Douglas B Chepeha; Francis P Worden; Matthew H Stenmark; Avraham Eisbruch; Carol R Bradford; Thomas E Carey Journal: JAMA Otolaryngol Head Neck Surg Date: 2013-12 Impact factor: 6.223
Authors: Philip E Castle; Mark Schiffman; Patti E Gravitt; Hortense Kendall; Stacy Fishman; Huali Dong; Allan Hildesheim; Rolando Herrero; M Concepcion Bratti; Mark E Sherman; Attila Lorincz; John E Schussler; Robert D Burk Journal: J Med Virol Date: 2002-11 Impact factor: 2.327
Authors: Matthew J Ferber; Erik C Thorland; Antoinette A T P Brink; Anton K Rapp; Leslie A Phillips; Renee McGovern; Bobbie S Gostout; Tak Hong Cheung; Tong Kwok Hung Chung; Wong Yick Fu; David I Smith Journal: Oncogene Date: 2003-10-16 Impact factor: 9.867
Authors: Giant C Lin; Adam Scheel; Sarah Akkina; Steven Chinn; Martin Graham; Christine Komarck; Heather Walline; Jonathan B McHugh; Mark E Prince; Thomas E Carey; Mark A Zacharek Journal: Int Forum Allergy Rhinol Date: 2013-08-26 Impact factor: 3.858
Authors: Keiko Akagi; Jingfeng Li; Tatevik R Broutian; Hesed Padilla-Nash; Weihong Xiao; Bo Jiang; James W Rocco; Theodoros N Teknos; Bhavna Kumar; Danny Wangsa; Dandan He; Thomas Ried; David E Symer; Maura L Gillison Journal: Genome Res Date: 2013-11-07 Impact factor: 9.043
Authors: M Re; F M Gioacchini; A Bajraktari; M Tomasetti; S Kaleci; C Rubini; A Bertini; G Magliulo; E Pasquini Journal: Eur Arch Otorhinolaryngol Date: 2017-04-21 Impact factor: 2.503
Authors: A Pähler Vor der Holte; I Fangk; S Glombitza; L Wilkens; H J Welkoborsky Journal: Eur Arch Otorhinolaryngol Date: 2019-12-12 Impact factor: 2.503
Authors: M Fulla; T Szafarowski; J Frias-Gomez; B Quiros; O Clavero; M Gomà; M A Pavon; O Jurek-Matusiak; H R Lares; M Mañós; L Alemany; M Mena; X Gonzalez Journal: Head Neck Pathol Date: 2020-01-08
Authors: Wesley H Stepp; Zainab Farzal; Adam J Kimple; Charles S Ebert; Brent A Senior; Adam M Zanation; Brian D Thorp Journal: Int Forum Allergy Rhinol Date: 2021-05-06 Impact factor: 5.426
Authors: A M Udager; J B McHugh; C M Goudsmit; H C Weigelin; M S Lim; K S J Elenitoba-Johnson; B L Betz; T E Carey; N A Brown Journal: Ann Oncol Date: 2018-02-01 Impact factor: 51.769